Reporting owner · CIK 0001827317
Nicholson Nur
Visual SEC Form 4 history across 2 companies, 6 transactions and 5 filings.
CTOChief Technology OfficerKailera Therapeutics, Inc.
Open-market mix
0%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Jan 25
−$284.3K
Sep 26
$0
Transaction texture
Ownership and ticket size
Average P/S size$71.1K
Median P/S size$69.9K
Direct6
Indirect0
Sep 07, 2026grant
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest transaction
sale at Apellis Pharmaceuticals, Inc. on Jan 29, 2025 valued at $24,357.
Review SEC filingLatest buy
No open-market insider purchase is available.
Latest sale
sale at Apellis Pharmaceuticals, Inc. on Jan 29, 2025 valued at $24,357.
Review SEC filingAssociated companies
Visual map of known reporting history
| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| KLRA | Nicholson Nur | CTO | grant | 220k | $0 | A | — | 09/09 | 09/07 | |
| APLS | Nicholson Nur | CTO | sale | 825 | -$2.43M | S | — | 01/30/2025 | 01/29/2025 | |
| APLS | Nicholson Nur | CTO | sale | 3.94k | -$12.0M | S | — | 01/23/2025 | 01/22/2025 | |
| APLS | Nicholson Nur | CTO | grant | 36.4k | $0 | A | — | 01/21/2025 | 01/21/2025 | |
| APLS | Nicholson Nur | CTO | sale | 2.14k | -$6.42M | S | — | 01/21/2025 | 01/17/2025 | |
| APLS | Nicholson Nur | CTO | sale | 2.63k | -$7.55M | S | — | 01/14/2025 | 01/13/2025 |
Nicholson Nur Insider Activity FAQ
SEC Form 4 context
Who is Nicholson Nur?
Nicholson Nur is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001827317.
Which companies has Nicholson Nur reported transactions for?
Kailera Therapeutics, Inc., Apellis Pharmaceuticals, Inc.
When was Nicholson Nur's latest insider buy?
No open-market insider purchase is available for this period.
When was Nicholson Nur's latest insider sale?
sale at Apellis Pharmaceuticals, Inc. on Jan 29, 2025 valued at $24,357.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.